The foundation of therapy for stable coronary artery disease (CAD) is optimal medical therapy, with or without revascularization, by either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG). Multiple studies have questioned the incremental benefit of PCI over optimal medical therapy.[@bib1], [@bib2] Invasive fractional flow reserve (FFR) has emerged as an important diagnostic tool to identify a subset of patients in whom revascularization may be beneficial.

There is a growing body of literature that has demonstrated both clinical and economic benefits associated with the use of FFR measurements to guide PCI in patients with stable CAD, with reductions in death, nonfatal myocardial infarction, and urgent revascularization.[@bib3], [@bib4], [@bib5] The studies on the utility of FFR in the population with acute coronary syndrome (ACS) are smaller and inconsistent in their conclusions,[@bib6], [@bib7] with some suggesting that the microvascular dysfunction associated with patients with ACS may lead to false-negative FFR results,[@bib7], [@bib8] whereas others maintain FFR are nonetheless valid in this setting.[@bib9], [@bib10], [@bib11], [@bib12] Despite the growing evidence base for FFR in patients with stable CAD and ACS, there is a paucity of data on its use in clinical practice. Specifically, no studies to date have investigated whether the landmark publications on FFR have influenced physician behaviour and affected clinical practice in terms of downstream revascularization decisions.

Accordingly, to address these gaps in knowledge, our aim was to determine the temporal trends in the population rates of FFR overall and for subsets of patients with stable CAD and ACS. We hypothesized that FFR rates would have increased substantially over time with a concomitant decrease in referrals for coronary revascularization.

Material and Methods {#sec1}
====================

This study was approved by the Institutional Research Ethics Board at Sunnybrook Health Sciences Centre at the University of Toronto, Ontario.

Context {#sec1.1}
-------

Ontario is the largest province in Canada with a population of 13.6 million. All residents have universal access to health care and hospital services through a publicly funded health care program administered by a single third-party payer, the Ontario Ministry of Health and Long Term Care (MOHLTC).

Data sources {#sec1.2}
------------

Our study used data collected in the CorHealth Ontario Cardiac Registry. The CorHealth Registry captures data from all 19 hospitals that provide invasive cardiac procedures across the province, including cardiac catheterization, PCI, and CABG.[@bib13], [@bib14] The CorHealth Cardiac Registry contains demographic, comorbidity, procedural, and anatomic variables, which have been validated through selected chart abstractions and core laboratory analyses.[@bib15], [@bib16], [@bib17] The registry contains a data field specifying the indication for the angiogram as stable CAD or ACS. This registry contains data on the use of FFR, as well as the number of stents used in PCI. Anatomic data were categorized as 1-, 2-, or 3-vessel disease based on the number of epicardial vessels with obstructive disease. We defined obstructive CAD as \> 70% obstruction in any of the left anterior descending artery, circumflex artery, or right coronary artery, or \> 50% obstruction in the left main artery based on visual assessment by the operator of the angiogram.[@bib18] Patients were classified on the basis of the initial revascularization treatment strategy, which was defined as PCI or CABG within 90 days of the index procedure. The 90-day window was chosen on the basis of previous literature and current wait times in Ontario.[@bib15], [@bib16], [@bib19], [@bib20]

Data from the CorHealth Cardiac Registry were linked using encrypted unique patient identifiers to population-based administrative databases housed at the Institute for Clinical Evaluative Sciences in Toronto, Ontario. Validated Institute for Clinical Evaluative Sciences--derived databases were used to identify diabetes (Ontario Diabetes Dataset),[@bib21] congestive heart failure (Ontario Congestive Heart Failure Dataset),[@bib22] and hypertension (Ontario Hypertension Dataset).[@bib23] Linkages were performed to the Canadian Institute for Health Information Discharge Abstract Database and the Ontario Health Insurance Plan physician claims database to confirm several cardiac status and risk factors using a look-back period of 3 to 20 years before the index coronary angiogram. Linkages to these population-level administrative databases were also used to identify interventional and surgical cardiac procedures occurring after the index coronary angiogram. The Institution Information System, which contains information about Ontario health care institutions funding by the MOHLTC, was used to classify hospitals as academic or community. Demographic information (age and gender) was determined through linkage with vital statistics in the Registered Persons Database.

Patient selection {#sec1.3}
-----------------

We included all the patients captured in the CorHealth database who underwent a coronary angiography in Ontario for CAD from January 1, 2010, to December 31, 2015. In our study, the unit of analysis was the angiogram.

The total cohort was divided into 3 subcohorts: (1) stable CAD subcohort, which included patients referred for angiography for the indication of stable CAD with a Canadian Cardiovascular Society functional angina classification of 0 to 4 and who were waiting for their coronary angiogram at home; (2) ACS subcohort, which included patients referred for angiography for unstable angina (UA), non--ST-elevation myocardial infarction, or ST-elevation myocardial infarction, with a classification of ACS as emergent, high risk, intermediate, or low risk; and (3) an indeterminate subcohort, which included patients who are not clearly in either of these 2 subcohorts. We choose this classification to ensure high specificity with patients in the stable CAD and ACS groups, because this was the main comparison of interest.

On the basis of the CorHealth registry, we ascertained if each angiogram was associated with an FFR. An additional subanalysis was conducted to assess clinical outcomes stratified by FFR result (positive \< 0.8 vs negative \> 0.8); this analysis was restricted to angiograms after April 5, 2013, because these data were only captured in the CorHealth registry from this date onward.

Outcome variable {#sec1.4}
----------------

Our primary outcome of interest was the monthly age- and sex-standardized population rate of FFR per 100,000 (direct standardization using the 2010 Ontario population). As a metric of FFR use per case, our secondary outcome was the monthly rate of FFR per 100 angiograms in the whole cohort and then in each of the stable CAD and ACS subcohorts. Finally, as a metric of FFR case selection over time, we also examined the proportion of positive FFR results per month over the study period.

Our clinical outcome of interest was to evaluate the proportion of patients who had a subsequent PCI and CABG within 3 months of the index angiogram. This time period was based on the upper limits of procedural wait-times in the province over that study period.[@bib24] We also evaluated the number of stents that were used for each subsequent PCI.

Statistical analysis {#sec1.5}
--------------------

For the trend analysis of FFR use rates over time, piecewise regression analyses were performed. The dependent variable was the age- and sex-standardized FFR use rate per 100,000 of the population or the rate of FFR use per 100 angiograms. We evaluated the impact on FFR use rates in response to the landmark study "Fractional Flow Reserve Guided PCI versus Medical Therapy in Stable Coronary Disease" (FAME 2 trial), which was published in September 2012.[@bib4] Residuals were plotted over time, and the Durbin--Watson statistic was used to determine whether first-order autocorrelation was present. If autocorrelation was present, the autoregressive parameters were included in the final piecewise regression model for correction. A simple *z* score test was used to determine the significance of the difference between the piecewise regression slopes. We repeated these analyses in subgroups of patients treated at academic centers vs community hospitals. All data analyses were performed using SAS version 9.4 (SAS Institute Inc, Cary, NC).

Results {#sec2}
=======

A total of 379,688 coronary angiograms were performed between January 1, 2010, and December 31, 2015. As shown in [Figure 1](#fig1){ref-type="fig"}, there were 122,571 angiograms performed for stable CAD and 134,769 angiograms performed for ACS. FFR was performed in 3.2% of the total cohort and in 4.6%, 2.7%, and 2.4% in the stable CAD, ACS, and indeterminate subcohorts, respectively.Figure 1Selection of patient's cohort. ACS, acute coronary syndrome; CCS, Canadian Cardiovascular Society; FFR, fraction flow reserve; IKN, unique identifier.

Baseline characteristics {#sec2.1}
------------------------

The baseline characteristics of the whole cohort and individually in the 3 subcohorts, stratified by FFR status (FFR vs non-FFR), are shown in [Table 1](#tbl1){ref-type="table"} and [Supplementary Tables S1-S3](#appsec1){ref-type="sec"}. In general, FFR was used more commonly in stable CAD cases with greater symptom burden, as quantified by the Canadian Cardiovascular Society class ([Supplementary Table S1](#appsec1){ref-type="sec"}). The converse was true in ACS cases, in which FFR was more frequently used in those with lower-risk presentations ([Supplementary Table S2](#appsec1){ref-type="sec"}). The baseline characteristics for the subgroup in which FFR results are reported, starting in April 5, 2013, are presented in [Supplementary Tables S4](#appsec1){ref-type="sec"} and [S5](#appsec1){ref-type="sec"}. In this subgroup of 178,792 angiograms, FFR was conducted in 7775 cases (4.3%). Overall, this subgroup was similar in terms of baseline characteristics to the overall cohort.Table 1Baseline characteristics in patients who underwent coronary angiography in Ontario between January 1, 2010, and December 31, 2015 (N = 379,688)VariableTotal N = 379,688FFR N = 12,303Non-FFR N = 367,385Standardized difference*P* valueDemographics Age Mean ± SD, y64.97 ± 12.1265.13 ± 10.6764.97 ± 12.160.040.15 Sex, female, N (%)131,899 (34.7%)4015 (32.6%)127,884 (34.8%)0.05\< 0.001Clinical presentation, N (%)\< 0.001 Elective stable CAD131,300 (34.6%)5432 (44.2%)125,868 (34.3%)0.20 Rule out CAD29,672 (7.8%)875 (7.1%)28,797 (7.8%)0.03 STEMI43,893 (11.6%)466 (3.8%)43,427 (11.8%)0.30 NSTEMI74,591 (19.6%)1964 (16.0%)72,627 (19.8%)0.10 UA67,891 (17.9%)3200 (26%)64,691 (17.6%)0.25 Unknown32,341 (8.5%)366 (3.0%)31,975 (8.7%)0.25Medical comorbidities, N (%) Previous MI140,548 (37%)5089 (41.4%)135,459 (36.9%)0.09\< 0.001 CVD29,599 (7.8%)902 (7.3%)28,697 (7.8%)0.020.05 Previous CABG44,392 (11.7%)1006 (8.2%)43,386 (11.8%)0.12\< 0.001 Previous PCI107,786 (28.4%)5703 (46.4%)102,083 (27.8%)0.39\< 0.001 DM123,316 (32.5%)4347 (35.3%)118,969 (32.4%)0.06\< 0.001 HTN265,543 (69.9%)9368 (76.1%)256,175 (69.7%)0.15\< 0.001 HLD249,569 (65.7%)9175 (74.6%)240,394 (65.4%)0.20\< 0.001 Current smoking78,359 (20.6%)2368 (19.2%)75,991 (20.7%)0.040.001 PVD26,115 (6.9%)865 (7.0%)25,250 (6.9%)0.060.50 CHF53,867 (14.2%)1280 (10.4%)52,587 (14.3%)0.12\< 0.001 Renal disease14,620 (3.9%)351 (2.9%)14,269 (3.9%)0.06\< 0.001LVEF%, N (%)\< 0.001 4: \< 20%5129 (1.4%)73 (0.6%)5056 (1.4%)0.08 3: 20%-34%17,316 (4.6%)405 (3.3%)16,911 (4.6%)0.07 2: 35%-49%34,088 (9%)1137 (9.2%)32,951 (9.0%)0.01 1: \> 50%138,144 (36.4%)5510 (44.8%)132,634 (36.1%)0.18 Unknown185,011 (48.7%)5178 (42.1%)179,833 (48.9%)0.14Angiographic findings, No. of diseased vessels, N (%)\< 0.001 0144,158 (38%)4313 (35.1%)139,845 (38.1%)0.07 1103,121 (27.2%)4141 (33.7%)98,980 (26.9%)0.15 271,658 (18.9%)2673 (21.7%)68,985 (18.8%)0.07 360,751 (16%)1176 (9.6%)59,575 (16.2%)0.20 Mean ± SD (N)1.13 ± 1.09 (379,688)1.06 ± 0.97 (12,303)1.13 ± 1.1 (367,385)0.07\< 0.001Hospital type\< 0.001 Academic207,476 (54.6%)7306 (59.4%)200,170 (54.5%)0.10 Community172,212 (45.4%)4997 (40.6%)167,215 (45.5%)0.10[^1]

Trends in FFR use {#sec2.2}
-----------------

As shown in [Figure 2](#fig2){ref-type="fig"}, the rate of FFR use (age- and sex-standardized population rate of FFR per 100,000) in Ontario increased substantially during the study period from approximately from 0.4 to 2.3 per 100,000 people per month. This increase in FFR use reflected an increased use per angiogram, as shown in [Figure 3](#fig3){ref-type="fig"}A-C. The monthly FFR use rate increased from 0.9 to 4.9 per 100 angiograms/month in the overall cohort ([Fig. 3](#fig3){ref-type="fig"}A). The rate of FFR use during the study period increased 1.5 times faster in the stable CAD (1.1 to 8.0 per 100 angiograms/month) ([Fig. 3](#fig3){ref-type="fig"}B) compared with the ACS population (0.6 to 4.5 per 100 angiograms/month) ([Fig. 3](#fig3){ref-type="fig"}C). However, this difference did not reach statistical significance (*z* score 0.14). As a reflection of case selection, despite the increase in overall rates of FFR per population and by angiogram, the proportion of FFR cases that were positive did not change significantly during the study period, remaining at approximately 28% ([Fig. 4](#fig4){ref-type="fig"}).Figure 2Monthly age- and sex-standardized FFR use rates per 100,000 population in Ontario (January 1, 2010, to December 31, 2015). CI, confidence interval; FFR, fraction flow reserve.Figure 3(**A**) Monthly age- and sex-standardized FFR use rates per 100 angiograms (January 1, 2010, to December 31, 2015). (**B**) Monthly age- and sex-standardized FFR use rates per 100 angiograms in patients with stable CAD (January 1, 2010, to December 31, 2015). (**C**) Monthly age- and sex-standardized FFR use rates per 100 angiograms in patients with ACS (January 1, 2010, to December 31, 2015). CI, confidence interval; FFR, fraction flow reserve.Figure 4Proportion of positive FFR results (April 5, 2013, to December 31, 2015). CI, confidence interval; FFR, fraction flow reserve.

As shown in [Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}A-C, there were minimal differences in the rates of FFR use after the publication of FAME-2 in September 2012 ([Supplementary Table S6](#appsec1){ref-type="sec"} shows details).

Trends in FFR use in academic vs community hospitals {#sec2.3}
----------------------------------------------------

As shown in [Supplementary Figure S1](#appsec1){ref-type="sec"}, the rate of FFR use (age- and sex-standardized population rate of FFR per 100,000 people/month) increased during the study period in academic and community hospitals from approximately 0.3 to 1.3 and from 0.1 to 1.1, respectively. The relative increase in FFR use per 100 angiograms per month was greater in community vs academic hospitals (0.5 to 5.2 and 1.6 to 4.6, respectively) ([Supplementary Fig. S1](#appsec1){ref-type="sec"}). The proportion of FFR cases that were positive did not change significantly during the study period, remaining at approximately 30% in academic hospitals and 26% in community hospitals ([Supplementary Fig. S2](#appsec1){ref-type="sec"}). As with our main findings, the publication of FAME-2 was associated with minimal differences in FFR use in both the academic and the community hospitals overall, as well as in the stable CAD and ACS populations (Supplementary [Figures S1](#appsec1){ref-type="sec"} and [S3](#appsec1){ref-type="sec"}).

Clinical outcomes {#sec2.4}
-----------------

As shown in [Table 2](#tbl2){ref-type="table"}, there were inconsistent observations insofar as subsequent revascularization. In the total cohort, a significantly higher proportion of cases in the FFR group were referred for PCI (35.7% vs 33.3%, *P* \< 0.001), whereas fewer cases in the FFR group were referred to CABG (10.8% vs 11.8%, *P* \< 0.001). This pattern was also seen in the stable CAD subgroup. In contrast, in the ACS group, we observed the opposite pattern, in which fewer cases in the FFR group underwent subsequent PCI (41.2% vs 54.5% *P* \< 0.001). Similar trends were observed in the subgroups of community vs academic hospitals ([Supplementary Table S7](#appsec1){ref-type="sec"}).Table 2Clinical outcomes in patients who underwent coronary angiogram in Ontario between January 1, 2010, and December 31, 2015Total cohortTotal, N = 379,688FFR, N = 12,303Non-FFR, N = 367,385Standardized difference*P* valueClinical outcomes, N (%) PCI within 3 mo126,572 (33.3%)4395 (35.7%)122,177 (33.3%)0.05\< 0.001 CABG within 3 mo44,794 (11.8%)1331 (10.8%)43,463 (11.8%)0.030.001No. of stents in PCI, N (%) 174,238 (58.7%)2629 (59.8%)71,609 (58.6%)0.030.28 234,160 (27%)1150 (26.2%)33,010 (27.0%)0.02 3+18,174 (14.4%)616 (14.0%)17,558 (14.4%)0.01Stent No. Mean ± SD1.62 ± 0.92 (126,572)1.6 ± 0.91 (4395)1.62 ± 0.92 (122,177)0.020.15Stable CAD subgroupTotal, N = 122,571FFR, N = 5671Non-FFR, N = 116,900Standardized difference*P* valueClinical outcomes, N (%) PCI within 3 mo32,679 (26.7%)1847 (32.6%)30,832 (26.4%)0.13\< 0.001 CABG within 3 mo16,683 (13.6%)527 (9.3%)16,156 (13.8%)0.14\< 0.001No. of stents in PCI, N (%) 118,316 (56%)1110 (60.1%)17,206 (55.8%)0.090.001 28973 (27.5%)467 (25.3%)8506 (27.6%)0.05 3+5390 (16.5%)270 (14.6%)5120 (16.6%)0.05Stent no. mean ± SD1.68 ± 0.97 (32,679)1.61 ± 0.91 (1847)1.69 ± 0.97 (30,832)0.080.001ACS subgroupTotal, N = 134,769FFR, N = 3679Non-FFR, N = 131,090Standardized difference*P* valueClinical outcomes, N (%) PCI within 3 mo72,918 (54.1%)1515 (41.2%)71,403 (54.5%)0.27\< 0.001 CABG within 3 mo17,067 (12.7%)479 (13.0%)16,588 (12.7%)0.010.51No. of stents in PCI, N (%) 143,845 (60.1%)889 (58.7%)42,956 (60.2%)0.030.50 219,488 (26.7%)422 (27.9%)19,066 (26.7%)0.03 3+9585 (13.1%)204 (13.5%)9381 (13.1%)0.01Stent no. mean ± SD1.59 ± 0.89 (72,918)1.61 ± 0.89 (1515)1.59 ± 0.89 (71,403)0.020.44Indeterminate subgroupTotal, N = 122,348FFR, N = 2953Non-FFR, N = 119,395Standardized difference*P* valueClinical outcomes, N (%) PCI within 3 mo20,975 (17.1%)1033 (35.0%)19,942 (16.7%)0.43\< 0.001 CABG within 3 mo11,044 (9%)325 (11.0%)10,719 (9.0%)0.07\< 0.001No. of stents in PCI, N (%) 112,077 (57.6%)630 (61.0%)11,447 (57.4%)0.070.07 25699 (27.2%)261 (25.3%)5438 (27.3%)0.05 3+3199 (15.3%)142 (13.7%)3057 (15.3%)0.05Stent no. mean ± SD1.65 ± 0.95 (20,975)1.59 ± 0.92 (1033)1.65 ± 0.96 (19,942)0.070.03[^2]

Subgroup analysis {#sec2.5}
-----------------

Similar to the overall group, in the subgroup analysis of angiograms after April 5, 2013, we found a higher proportion of cases in the FFR group were referred for PCI (36.3% vs 33.8%, *P* \< 0.001) ([Supplementary Table S4](#appsec1){ref-type="sec"}). We compared angiograms with positive vs negative FFR results ([Supplementary Table S5](#appsec1){ref-type="sec"}). The FFR was positive (\<0.8) in 2153 cases (27.7%). As expected, a significantly higher proportion of cases with positive FFR results underwent subsequent revascularization. Of note, 1631 (29%) of the 5622 cases in the negative FFR group underwent PCI. Further characteristics of these patients are shown in [Supplementary Table S8](#appsec1){ref-type="sec"}.

Discussion {#sec3}
==========

We found a 5-fold increase in the use of FFR in angiograms across Ontario between 2010 and 2015. Case selection for FFR remained almost the same with approximately one-quarter of FFR cases being positive over time. FFR was used more commonly in stable CAD cases with greater symptom burden, as a rule-in procedure. In contrast, in the ACS cases, FFR was more frequently used in those with lower-risk presentations, as a rule-out procedure. Consistent with this pattern, there was higher subsequent PCI referral rates observed in the stable CAD subcohort compared with the ACS subcohort.

Previous studies have shown an increase in the use of FFR since the seminal FAME study, focusing on practice from 2001 to 2013.[@bib25], [@bib26], [@bib27], [@bib28], [@bib29] Indeed, more than 70% of physicians thought that the FAME trial led to more widespread use of FFR.[@bib25] Harle et al.[@bib29] found a very low rate of FFR; nonetheless, they observed an increasing trend in use over the course of the study period. The use of FFR was particularly low in patients with multivessel disease. There was wide variation in FFR use across the 38 hospitals participating in the study.[@bib29] Our study builds on this previous literature by evaluating FFR use in a more contemporary era. We found an ongoing increase in the use of FFR in patients across Ontario, which was predominantly driven by the use in cases with stable CAD. Although we did find a higher rate of FFR use in multiple-vessel disease at approximately 10% compared with earlier studies (∼2.5%), this was lower than 1- or 2-vessel disease.[@bib29] We did not find that the publication of FAME-2 was associated with any acceleration in the increase in use, and if anything, an attenuation in the total cohort and even a statistically significant decrease in the ACS subcohort. We would emphasize that these decreases are very small (0.13 FFR per 100,000) and therefore of no clinical significance. We hypothesize that this is because this additional literature reinforced the acceptance of FFR, rather than modified previous clinical attitudes.

Our findings on the FFR use trends in the ACS population were unexpected. Despite the relative paucity of data on its validity, the rate of FFR use in patients with ACS was relatively high at 2.6% and increased throughout the study period. The different symptom burden and risk in the stable CAD and ACS cases merit discussion. The fact that patients with stable CAD undergoing FFR were more symptomatic suggests that this was used as a test to confirm severe disease when anatomic features did not suggest this. In contrast, the lower risk of patients with ACS undergoing FFR suggest the opposite---that FFR was done to rule out a significant lesion.

Our hypothesis regarding these opposite intentions is further suggested by the inconsistent observations in subsequent revascularization in the populations. In the stable CAD subcohort, a significantly higher proportion of cases in the FFR group were referred for PCI, in contrast to the ACS cases. This reinforces our inference that FFR was applied as a rule-in tool for stable CAD vs a rule-out tool in patients with ACS. Unfortunately, only a portion of our cohort had information on the results of the FFR, and even in these cases there was a relative lack of granular information. For example, we are not able to confirm if the FFR in ACS cases was performed on a nonculprit lesion. Moreover, we found that approximately 29% of cases with a negative FFR had subsequent PCI. It is likely that this was PCI in a different coronary artery, and indeed, approximately 40% of those cases were multiple-vessel disease. That said, we lack the necessary granularity in the registry to fully understand this observation, but it merits further study. If indeed PCI was performed in FFR-negative cases, it may suggest that some physicians do not have as much confidence in FFR results in comparison with their visual assessment of the angiogram, a finding that if true should be a target for both education and quality improvement efforts.

Study limitations {#sec3.1}
-----------------

Our study must be interpreted in the context of several additional limitations that merit discussion. Given the availability of FFR data in the CorHealth registry; the study cohort could only contain angiograms performed after 2010; as such, we cannot comment on practice change that corresponded to the initial FAME publications. Second, our data showed that FFR use resulted in higher rates of PCI referrals in the total cohort and in the stable CAD subcohort; however, we are unable to comment whether this translated to improved outcomes. This is an area of ongoing research by our group. Third, our indeterminate subcohort was relatively large. We elected to be conservative in our classification of stable CAD vs ACS because this was the main comparison of interest. This results in a high specificity for cases allocated to the stable CAD or ACS groups, but correspondingly, a large proportion classified as indeterminate. Because we only included patients in our cohort with a referral for the investigation of coronary disease, it is likely that most of indeterminate patients were, in fact, either patients with stable CAD or patients with ACS; on the basis of the information in the registry, we were simply not able to classify them accurately. Indeed, the observation that the indeterminate subcohort showed the same upward trend in FFR use as the others reinforces this point. Finally, our observations were at an ecologic level, and as such, we do not imply any causality. Therefore, it is important that our inferences be considered hypothesis generating and not conclusive.

Conclusions {#sec4}
===========

There is a strong temporal trend of increasing FFR use overall and in both subsets of patients with stable CAD and ACS. We found that case selection, as reflected by the proportion of positive FFR results, has remained relatively constant over time.
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[^1]: ACS, acute coronary syndrome; CABG, coronary artery bypass graft; CAD, coronary artery disease; CHF, congestive heart failure; CVD, cerebrovascular disease; DM, diabetes mellitus; FFR, fractional flow reserve; HLD, hyperlipidemia; HTN, hypertension; LVEF, left ventricular ejection fraction; MI, myocardial infarction; N, refers to patient's number; NTEMI, non--ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; SD, standard deviation; STEMI, ST-elevation myocardial infarction; UA, unstable angina.

[^2]: ACS, acute coronary syndrome; CABG, coronary artery bypass graft; CAD, coronary artery disease; N, refers to patient's number; PCI, percutaneous coronary intervention; SD, standard deviation.
